Acquire the license to the best health content in the world
Contact Us

TPN-Linked Hyperglycemia Ups Death for Non-Critically Ill

Total parenteral nutrition linked to 5.6-fold higher in-hospital mortality risk for noncritically ill

TPN-Linked Hyperglycemia Ups Death for Non-Critically Ill

THURSDAY, Jan. 3 (HealthDay News) -- Non-critically ill hospitalized patients who develop hyperglycemia after total parenteral nutrition (TPN) are more than five times more likely to die in the hospital, according to research published online Dec. 6 in Diabetes Care.

Gabriel Olveira, Ph.D., of the Carlos Haya University Hospital in Málaga, Spain, and colleagues conducted a prospective, multicenter study involving 605 non-critically ill hospitalized patients who were prescribed TPN.

The researchers found that non-critically ill hospitalized patients with average blood glucose levels above 180 mg/dL in response to TPN had a 5.6-fold increase in the risk of mortality, compared with those whose blood glucose levels remained below 140 mg/dL. This increased risk persisted even after accounting for numerous factors, including patient age, sex, nutritional status, diabetes or hyperglycemia prior to TPN, diagnosis, previous comorbidity, insulin units given, albumin, C-reactive protein, glycated hemoglobin levels, or infectious complications.

"In conclusion, the results show that hyperglycemia in non-critically ill patients receiving TPN is associated with increased in-hospital mortality. The data suggest that the goal of metabolic control in non-critically ill patients (with or without diabetes) receiving TPN should be to reach a mean blood glucose level of <180 mg/dL," the authors write. "This study opens the door to further prospective studies in non-critically ill patients to determine whether stricter blood glucose control during TPN infusion improves the outcome for the patients and reduces mortality."

Full Text (subscription or payment may be required)

Physician's Briefing